The BIM deletion polymorphism was reported to be associated with primary resistance to or a short PFS with epidermal growth factor receptor (EGFR) TKI in advanced EGFR-mutant NSCLC (24, 25). This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.